Explore how pharmacokinetic studies prove generic drugs are bioequivalent to brand names, focusing on Cmax, AUC, and FDA standards for therapeutic equivalence.
read more
Quality by Design (QbD) is now the standard for generic drug development, replacing outdated testing methods with science-based control. Learn how QbD improves bioequivalence, cuts approval times, and reduces costs-while avoiding common pitfalls.
read more
Bioequivalence for inhalers, patches, and injections ensures generic drugs deliver medicine as effectively as brand-name versions. Unlike pills, these systems require detailed testing of particle size, release rates, and delivery mechanics to guarantee safety and performance.
read more